Test Catalog

Test Id : MTRNA

Trichomonas vaginalis, Nucleic Acid Amplification, Varies

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detection of Trichomonas vaginalis in urine and male patient specimens

Method Name
A short description of the method used to perform the test

Transcription Mediated Amplification

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

T.vaginalis, Misc, Amplified RNA

Aliases
Lists additional common names for a test, as an aid in searching

T vag

Trichomoniasis

Specimen Type
Describes the specimen type validated for testing

Varies

Necessary Information

Specimen source is required.

ORDER QUESTIONS AND ANSWERS

Question ID Description Answers
SRC6 SOURCE:

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Submit only 1 of the following specimens:

 

Specimen Type: Urine

Supplies: Aptima Urine Transport Tube (T582)

Container/Tube: Aptima Urine Specimen Transport Tube

Specimen Volume: 15 to 20 mL

Collection Instructions:

1. Patient should not have urinated for at least 1 hour prior to specimen collection.

2. Patient should collect first portion of random voided urine (first part of stream) into a sterile, plastic, preservative-free container.

3. Transfer 2 mL of urine into the Aptima urine specimen transport tube using the disposable pipette provided within 24 hours of collection. The correct volume of urine has been added when the fluid level is between the black fill lines on the Aptima urine transport tube.

 

Specimen Type: Urine (following prostatic massage)

Supplies: Aptima Urine Transport Tube (T582)

Container/Tube: Aptima Urine Specimen Transport Tube

Specimen Volume: 15 to 20 mL

Collection Instructions:

1. Patient should not have urinated for at least 1 hour prior to specimen collection.

2. Patient should void a small amount of urine prior to prostatic massage. Pre-massage urine can be discarded or submitted for other testing as applicable.

3. Patient then ceases voiding and a prostatic massage is performed by the urologist or other health care professional.

4. Collect post-massage urine into a sterile, plastic, preservative-free container.

5. Transfer 2 mL of post-massage urine specimen into the Aptima urine specimen transport tube using the disposable pipette provided within 24 hours of collection. The correct volume of urine has been added when the fluid level is between the black fill lines on the Aptima urine transport tube.

 

Specimen Type: Urethral

Supplies: Swab, Aptima Male/Female Collection (T583)

Container/Tube: Aptima Collection Unisex Swab

Specimen Volume: Swab

Collection Instructions:

1. Urethral specimens must be collected using an Aptima Collection Unisex Swab.

2. Patient should not have urinated for at least 1 hour prior to collection.

3. With a rotating movement, insert swab (blue shaft) 2 to 4 cm into urethra.

4. Once inserted, rotate swab gently at least 1 full rotation using sufficient pressure to ensure swab comes into contact with all urethral surfaces. Allow swab to remain inserted for 2 to 3 seconds.

5. Place swab in the Aptima transport tube provided in collection kit. Snap off swab at score line so swab fits into closed tube.

6. Cap tube securely and label tube with patient's entire name and collection date and time.

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

See Specimen Required

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Midstream urine specimen
Over-filled or under-filled urine transport tubes
Transport tubes containing a cleaning swab or more than 1 swab
Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Refrigerated (preferred) 30 days APTIMA VIAL
Ambient 30 days APTIMA VIAL

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detection of Trichomonas vaginalis in urine and male patient specimens

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Trichomonas vaginalis (TV) is a protozoan parasite that commonly infects the genital tract of men and women. It is now considered to be the most common curable sexually transmitted infection (STI) agent, with an estimated 3.7 million infected individuals in the United States.(1-4) Although up to 70% of infected individuals are asymptomatic, infections may be associated with vaginitis, urethritis, and cervicitis in women, and urethritis and prostatitis in men.(3) Patients that are infected with T vaginalis have an increased risk of acquiring other sexually transmitted infections such as HIV, while infections in pregnant women are associated with premature labor, low birth-weight offspring, premature rupture of membranes, and post-hysterectomy/post-abortion infection.(3)

 

Symptoms of T vaginalis overlap considerably with other sexually transmitted infections; therefore, laboratory diagnosis is required for definitive diagnosis. The most commonly used method for detection is microscopic examination of a wet-mount preparation of vaginal secretions. However, this method has only 35% to 80% sensitivity compared with culture.(5) Culture also suffers from relatively low sensitivity (38%-82%) when compared to molecular methods.(5) Culture is technically challenging and takes 5 to 7 days to complete. Molecular methods, such as the Aptima T vaginalis assay, offer high sensitivity and specificity for detection of trichomoniasis. The Aptima test utilizes target capture, transcription-mediated amplification (TMA), and hybridization protection assay (HPA) technologies for detection of T vaginalis ribosomal RNA (rRNA).

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Interpretation
Provides information to assist in interpretation of the test results

A positive result is considered indicative of current or recent Trichomonas vaginalis infection (trichomoniasis).

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This assay is not FDA approved for urine and specimens collected from male patients. However, the performance characteristics of this test have been established by Mayo Clinic in accordance with CLIA-guidelines.

 

Reliable results are dependent on adequate specimen collection. Because the transport system used for this assay does not permit microscopic assessment of specimen adequacy, training of clinicians in proper specimen collection techniques is necessary.

 

Therapeutic failure or success cannot be determined with the APTIMA Trichomonas vaginalis assay since nucleic acid may persist following appropriate antimicrobial therapy.

 

Results from the APTIMA T vaginalis assay should be interpreted in conjunction with other clinical data and symptoms.

 

A negative result does not preclude a possible infection because results are dependent on adequate specimen collection. Test results may be affected by improper specimen collection, pre-analytical errors, technical errors, or target levels below the assay limit of detection. Furthermore, a negative result does not preclude a possible infection because the presence of Trichomonas tenax or Pentatrichomonas hominis in a specimen may affect the ability to detect T vaginalis rRNA.

 

Assay performance of the APTIMA T vaginalis assay has not been evaluated in the presence of Dientamoeba fragilis.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Weinstock H, Berman S, Cates W Jr: Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10

2. Soper D: Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol. 2004 Jan;190(1):281-290

3. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention: Trichomoniasis-CDC Fact Sheet. Centers for Disease Control and Prevention (CDC); Reviewed February 27, 2020. Accessed September 10, 2020. Available at www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm

4. Schwebke JR, Burgess D: Trichomoniasis. Clin Microbiol Rev. 2004 Oct;17(4):794-803

5. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM: Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis. 2002 Sep;35(5):576-580

Method Description
Describes how the test is performed and provides a method-specific reference

The APTIMA Trichomonas vaginalis Assay combines the technologies of target capture, transcription-mediated amplification (TMA), and hybridization protection assay (HPA) for detection of 16S rRNA from T vaginalis.(Package insert: Aptima Trichomonas vaginalis Assay. 503684 Hologic, Inc; Rev. 004 09/2018)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 to 3 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

87661

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MTRNA T.vaginalis, Misc, Amplified RNA 46154-1
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
SRC6 SOURCE: 31208-2
35034 T.vaginalis, Misc, amplified RNA 46154-1

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports